LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease von Jennings, Danna, Huntwork‐Rodriguez, Sarah, Vissers, Maurits F.J.M., Daryani, Vinay M., Diaz, Dolores, Goo, Marisa S., Chen, John J., Maciuca, Romeo, Fraser, Kyle, Mabrouk, Omar S., Wetering de Rooij, Jeroen, Heuberger, Jules A.A.C., Groeneveld, Geert Jan, Borin, Marie T., Cruz‐Herranz, Andrés, Graham, Danielle, Scearce‐Levie, Kimberly, De Vicente, Javier, Henry, Anastasia G., Chin, Peter, Ho, Carole, Troyer, Matthew D.

Volltext

Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti‐inflammatory 5‐lipoxygenase‐activating protein inhibitor von Bain, Gretchen, King, Christopher D., Schaab, Kevin, Rewolinski, Melissa, Norris, Virginia, Ambery, Claire, Bentley, Jane, Yamada, Masanori, Santini, Angelina M., Wetering de Rooij, Jeroen, Stock, Nicholas, Zunic, Jasmine, Hutchinson, John H., Evans, Jilly F.

Volltext

Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7 von BOONSTRA, Andre, LIU, Bi-Sheng, BAUMAN, Lisa A, RAHIMY, Mohamad, APPLEMAN, James R, FREDDO, James L, REESINK, Hendrik W, DE KNEGT, Robert J, JANSSEN, Harry La, GROOTHUISMINK, Zwier Ma, BERGMANN, Jilling F, DE BRUIJNE, Joep, HOTHO, Daphne M, HANSEN, Bettina E, VLIET, Andre A.van, DE WETERING DE ROOIJ, Jeroen Van, FLETCHER, Simon P

Volltext

Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design von HOTHO, Daphne M, DE BRUIJNE, Joep, SCHINKEL, Janke, MOLENKAMP, Richard, DE WETERING DE ROOIJ, Jeroen Van, VLIET, Andre Van, JANSSEN, Harry La, DE KNEGT, Robert J, REESINK, Hendrik W, O'FARRELL, A. Marie, BOYEA, Teresa, JIANKE LI, BRACKEN, Michele, XIN LI, CAMPBELL, David, GULER, Hans-Peter, WEEGINK, Christine J

Volltext

Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor von de Bruijne, Joep, Bergmann, Jilling F, Weegink, Christine J, van Nieuwkerk, Carin M J, de Knegt, Robert J, Komoda, Yasumasa, van de Wetering de Rooij, Jeroen J, van Vliet, Andre, Jansen, Peter L M, Molenkamp, Richard, Schinkel, Janke, Reesink, Hendrik, Janssen, Harry L A

Volltext

Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study von Reesink, Hendrik W., Zeuzem, Stefan, Weegink, Christine J., Forestier, Nicole, van Vliet, Andre, van de Wetering de Rooij, Jeroen, McNair, Lindsay, Purdy, Susan, Kauffman, Robert, Alam, John, Jansen, Peter L.M.

Volltext

Pharmacodynamics, pharmacokinetics and safety of GSK 2190915, a novel oral anti‐inflammatory 5‐lipoxygenase‐activating protein inhibitor von Bain, Gretchen, King, Christopher D., Schaab, Kevin, Rewolinski, Melissa, Norris, Virginia, Ambery, Claire, Bentley, Jane, Yamada, Masanori, Santini, Angelina M., van de Wetering de Rooij, Jeroen, Stock, Nicholas, Zunic, Jasmine, Hutchinson, John H., Evans, Jilly F.

Volltext

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Biomarkers of MIN-102 (Leriglitazone) (4149) von Meya, Uwe, Pina, Guillem, Pascual, Silvia, Cerrada-Gimenez, Marc, Pizcueta, Pilar, Martinell, Marc, Eckland, David, Wetering de Rooij, Jeroen v.d.

Volltext